Histrelin SC implant (Supprelin LA®)

OFFICE ADMINISTRATION 

Indications for Prior Authorization:

  • Central precocious puberty

Patients must meet the following criteria for the indication(s) above:

  • Patients two years and older. Discontinue at age 11 years for girls and 12 years for boys

All of the following must be met as a condition(s) for coverage:

  • Age between two and 12 years
  • Trial/failure/adverse effects of leuprolide depot
    • 0.3mg/kg/dose IM q month (Lupron Depot PED [one month]) OR
    • 11.25mg to 30mg IM q 3 months (Lupron Depot PED [3 month])

The Following Conditions Do Not Meet the Criteria for Use as Established by the WHA P & T Committee:

  • Idiopathic short stature
  • Ovarian cancer
  • Prophylaxis for chemo therapy induced gonadal injury
  • Considered experimental and investigational for all other indications outside of the FDA indication because there is insufficient evidence in peer reviewed literature

Dose:

  • One implant (50mg) q 12 months

Approval:

One year


 

Last review date: December 9, 2016

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.